TRDA Entrada Therapeutics, Inc.
$4.84▲ +9.75%
Healthcare
Other
After hours
$4.72▼ -2.55%
Oct 28, 4:46 PM ET
Volume 409.1K
Avg Volume (10D) 462.3K
Key Metrics & Fundamentals
Market Cap
$188.45M
P/E Ratio
–
Div Yield
0.00%
52W Range
4.11 - 16.45
% vs 50 MA
-21.61%
% vs 200 MA
-45.19%
RSI-14
43.5
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.42
Free Cash Flow
-$32.47M
Gross Rev
$898,000
Gross Profit
$898,000
EBITDA
-$44.12M
COGS
–
Operating Exp
$45.86M
Operating Income
-$44.96M
EBIT
-$44.96M
Pretax Income
-$42.73M
Net Income
-$42.76M
EPS (Diluted)
-1.01
Price & Volume History
Loading chart…
Recent News
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
GlobeNewswire · Oct 21, 2026 7:00 AM ET
What's Going On With Entrada Therapeutics Stock Wednesday?
Benzinga · Oct 14, 2026 12:47 PM ET
Entrada Says First Cohort of ENTR-601-45 Phase 1/2 Trial Shows 'Positive' Safety Results in Duchenne Muscular Dystrophy
MT Newswires · Oct 14, 2026 8:13 AM ET
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
GlobeNewswire · Oct 14, 2026 7:00 AM ET
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
GlobeNewswire · Oct 14, 2026 7:00 AM ET
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
GlobeNewswire · Sep 10, 2026 7:00 AM ET
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 2, 2026 4:30 PM ET
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 5, 2026 9:00 AM ET
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 5, 2026 7:00 AM ET
Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing
MT Newswires · Aug 3, 2026 5:33 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See TRDA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.